IA
EBS icon

IndexIQ Advisors’s Emergent Biosolutions EBS Stock Holding History

IndexIQ Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,620
Closed -$324K – 1185
2020
Q4 		$324K Buy
3,620
+374
+12% +$34.3K 0.01% 622
2020
Q3 		$335K Buy
3,246
+177
+6% +$19.1K 0.01% 377
2020
Q2 		$243K Sell
3,069
-364
-11% -$27.1K 0.01% 418
2020
Q1 		$199K Buy
+3,433
New +$198K 0.01% 307

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IndexIQ Advisors's EBS Position: Q1 2021 in Review

IndexIQ Advisors sold out of Emergent Biosolutions (EBS) in Q1 2021, closing a stake of 3,620 shares — an estimated $324K sold.

IndexIQ Advisors first reported a position in EBS in Q1 2020 and held it in 4 quarters. The position peaked at $335K in Q3 2020. 340 funds tracked by Wall St. Rank hold EBS as of Q1 2021.

  • IndexIQ Advisors reported no remaining Emergent Biosolutions position as of Q1 2021 after selling out during the quarter.
  • IndexIQ Advisors sold 3,620 Emergent Biosolutions shares in Q1 2021, an estimated $324K.
  • IndexIQ Advisors first reported a position in Emergent Biosolutions in Q1 2020 and held it in 4 quarters.
  • IndexIQ Advisors's Emergent Biosolutions position peaked at $335K in Q3 2020.
  • 340 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2021.

Based on IndexIQ Advisors's 13F filing for Q1 2021, filed 7 May 2021.